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The government owns rights in the present invention 
pursuant to NIH grants AI 28845 and AI33577. 
This application is a continuation-in-part application of 
U.S. Ser. No. 07/964 607 filed Oct. 21, 1992, which is a 
continuation-in-part application of U.S. Ser. No. 07/454, 
298, filed Dec. 21, 1989, since issued as U.S. Pat. No. 
55,159,065 on Oct. 27, 1992. U.S. Ser. No. 07/964,607 and 
U.S. Pat. No. 5,159,065 are incorporated by reference 
herein. 
BACKGROUND OF THE INVENTION 
1. Field of the Invention 
The present invention relates generally to sapphyrin com 
pounds, and particularly, to water-soluble sapphyrin deriva 
tives. Water-soluble sapphyrins include sapphyrins having 
hydroxy, hydroxyalkyl, oxyalkyl, carboxyamide, polyhy 
droxy or carbohydrate substituents, for example; and are 
useful for transport, drug delivery, DNA binding, photody 
namic therapy and DNA cleavage. 
2. Description of the Related Art 
Sapphyrins are large pyrrole-containing macrocyclic ana 
logues of the porphyrins. A number of expanded porphyrin 
systems are now known. However, only a few fully conju 
gated examples have been reported that contain more that 
four pyrrolic subunits, namely the smaragdyrins, sapphyrins, 
pentaphyrins, hexaphyrins, and superphthalocyanines 
among others. Sapphyrin, in its generalized substituent-free 
form, is represented by structure I. 
3 2 23 22 
12 13 
Sapphyrin, first discovered serendipitously by Wood 
ward' is one of the more intriguing products to emerge from 
initial studies directed towards the synthesis of Vitamin 
B2.’ It is a 22 pi-electron pentapyrrolic macrocycle which 
exhibits an intense Soret-like band at about 450 nm (CHCl) 
along with weaker Q-type transitions in the 620 to 690 nm 
region. These optical properties, along with the presence of 
a large central cavity which could serve for metal binding, 
renders sapphyrin useful for certain biomedical applications, 
including photodynamic therapy (PDT). 
In addition to the above, certain expanded porphyrins, 
including especially those of the sapphyrin series, have been 
found to act as halide anion chelating agents in both solution 
and the solid state. 
Unfortunately, all sapphyrins known at the time of this 
invention were essentially insoluble in water and were all of 
such simple character in terms of peripheral substituents, 
that only those bearing hydrogen or alkyl were known. 
These two deficiencies limited the potential utility of sap 
phyrins for any applications associated with their use at or 













ing partial or complete association with an aqueous envi 
Onet. 
Furthermore, it was recognized that the synthesis of one 
or more water-soluble sapphyrins would represent a consid 
erable advantage, not only in terms of anion recognition and 
transport, but also because it would allow for a detailed 
study of the basic binding phenomena in aqueous media. 
This latter would be particular true if said water-soluble 
sapphyrin were neutral in character. 
There still remains considerable scope for the design of 
improved chemotherapeutic compounds which act upon 
DNA once inside a target cell. Since currently available 
chemotherapeutic agents have complex structures, or com 
plicated modes of interaction with their targets that preclude 
systematic improvement, the development of a novel class 
of DNA binding compounds would open up new avenues for 
the design of improved therapeutics. In this regard, a class 
of compounds that can be modified in a number of different 
ways whilst maintaining their overall structure would be 
particularly advantageous. The same is true for compounds 
that can be activated by light, or other means, to produce 
singlet oxygen or hydroxyl radicals, once bound to DNA. 
These considerations provided the present inventors with 
further impetus for the design and synthesis of improved 
sapphyrins such as those embodied by the present invention. 
SUMMARY OF THE INVENTION 
The present invention addresses these and other short 
comings in the prior art through the synthesis of several 
water-soluble sapphyrin derivatives. 
The present invention provides sapphyrin derivatives hav 
ing the structure: 
R2 Ri R10 R9 
R5 
wherein each of R-R'' are independently hydrogen, alkyl, 
alkene, alkyne, halide, alkylhalide, hydroxyalkyl, hydroxy 
alkylamido, glycol, polyglycol, thiol, thioalkyl, aminoalkyl, 
carboxyalkyl, carboxyamidealkyl, oxyalkyl, alkoxyalkyl, 
aryloxyalkyl, oxyhydroxyalkyl, alkyloxycarbonyl, aryloxy 
carbonyl, aldehyde, ether, ketone, carboxylic acid, phos 
phate, phosphonate, sulfate, phosphate substituted alkyl, 
phosphonate substituted alkyl, or sulfate substituted alkyl, 
such that the total number of carbon atoms in each substitu 
ent R is less than or equal to 100. 
The novel aspect of the water-soluble sapphyrins is that at 
least one of R-R' is of the formula (CH), A 
(CH), B, where A is alkyl having from 1-4 carbon atoms, 
oxy, sulfide, amide, carbonyl, alkenyl, alkynyl, alkylhalide, 
hydroxyalkyl, glycol, polyglycol, alkylthiol, substituted 
alkyl, phosphate, phosphonate, sulfate, phosphate substi 
tuted alkyl, phosphonate substituted alkyl, sulfate substi 
tuted alkyl, carboxy, carboxyamide, ester, thiol-substituted 




hydroxyalkyl, oxyalkyl, carboxy, carboxyalkyl, glycol, 
polyglycol, thiol, aminoalkyl, phosphate, phosphonate, sul 
fate, phosphate substituted alkyl, phosphonate substituted 
alkyl, sulfate substituted alkyl, substituted hydroxyalkyl, 
saccharide, saccharide derivative, or polysaccharide; and in 
and m are independently an integer from 0 to 4. 
Derivatized carboxyamide may be described as having the 
formula CONR'R'', where R'' and R' may be separately 
and independently H, alkyl, alkyl halide, hydroxyalkyl, 
glycol, polyglycol, alkylthiol, or amide. 
In a preferred embodiment, A is alkyl having 1-4 carbon 
atoms, oxy, sulfide, amide, carbonyl, carboxy, carboxya 
mide, ester, thiol-substituted carboxyamide, or derivatized 
carboxyamide; and B is hydroxy, hydroxyalkyl, saccharide, 
saccharide derivative or polysaccharide. In another preferred 
embodiment, B is hydroxyalkyl, most preferably, 
hydroxymethyl, hydroxyethyl, hydroxypropyl, or hydroxy 
butyl. In a more preferred embodiment, a water-soluble 
sapphyrin has R, R-R', and R' selected from the substitu 
ents of Tables 2 or 3. Most preferably, R, R, or R is of the 
formula (CH)-A-(CH2), B, where B is hydroxyalkyl 
or saccharide. Particular water-soluble Sapphyrins are exem 
plified by sapphyrins A1-A27 of Table 2 or B1-B8 of Table 
3. 
In further preferred embodiments of the present invention, 
A is carboxyamide and B is hydroxyalkyl or saccharide, A 
is oxy and B is oxyalkyl, A is alkenyl and B is hydroxy. 
In another preferred embodiment of the water-soluble 
sapphyrins of the present invention, B is saccharide or 
saccharide derivative, and more preferably, the saccharide or 
saccharide derivative is selected from those set forth in Table 
1. Where B is a polysaccharide, the polysaccharide is 
preferably chitosan, alginic acid, hyaluronic acid, or dextran. 
Water-soluble sapphyrins are particularly desirable where 
one would like to exploit the various surprising properties of 
the sapphyrin macrocycle in connection with human or 
animal applications. "Water-soluble' means soluble in aque 
ous fluids to about 1 mM or better. Water-solubility may be 
achieved by hydroxylation of the sapphyrin macrocycle, and 
the nature of the hydroxylation is not particularly critical so 
long as at least one, and preferably two, or three hydroxyl 
groups per Sapphyrin macrocycle are incorporated into the 
Still CLIre. 
One means for introducing hydroxyl groups into the 
sapphyrin macrocycle structure is simply through the addi 
tion of hydroxyalkyl substituents to the basic sapphyrin 
macrocycle unit, wherein the added substituents include one 
or more hydroxyl groups within their structures. An alter 
native means of achieving polyhydroxylation is through the 
addition of Sugar moieties such as a saccharide, polysaccha 
ride, saccharide derivative or aminosaccharide, to the sap 
phyrin macrocycle structure. In such cases, it has been found 
that the addition of a single saccharide molecule to a 
sapphyrin macrocycle will achieve a degree of water solu 
bility. These structures are referred to broadly herein as 
simply sapphyrin-saccharide compounds or derivatives. The 
nature of the saccharide is not particularly critical to the 
achievement of water solubility. 
Water-soluble sapphyrin derivatives are of interest in a 
variety of applications including photodynamic therapy 
(PDT), DNA recognition and modification, cellular recog 
nition, and transport. In regard to PDT, water-soluble sap 
phyrins may be used as photosensitization agents for the 
generation of cytotoxic singlet O in vitro, ex vivo or in 
vivo; as well as photodynamic inactivation of infectious 
agents having membranous envelopes. As such they may be 














blood samples, such as, for example, the hepatitis viruses 
HBV and NANB, and especially HIV-1. In this process, 
sapphyrin localizes selectively at or near the morphologi 
cally characteristic viral envelope. Upon photoirradiation, it 
catalyzes the formation of highly reactive singlet oxygen 
which, in turn, destroys the essential membrane envelope 
thus killing the virus and eliminating its infectivity; see U.S. 
Pat. No. 5,041,078, incorporated herein by reference. 
The search for compounds for use in in vivo cellular 
transport and uptake, where diffusion across a membrane is 
involved, led the inventors to synthesize and characterize the 
range of novel water-soluble sapphyrin derivatives 
described herein. It is contemplated that water-soluble sap 
phyrin derivatives will have utility in both photophysical 
and biological embodiments. For example, it is envisioned 
that these new sapphyrins will have improved solubility 
and/or phosphate anion chelation properties, rendering them 
of use in protocols such as anti-viral transport and RNA/ 
DNA recognition and binding. 
DETAILED DESCRIPTION OF THE 
PREFERRED EMBODIMENTS 
The synthesis of various sapphyrins and uses thereof have 
been previously reported', see also U.S. Pat. Nos. 
5,159,065, 5,120,411, 5,041,078 and 5,302.714; each of 
these references is incorporated herein by reference. Struc 
tural information is available for a limited number of alkyl 
substituted sapphyrins". The present invention concerns 
water-soluble sapphyrins that overcome known deficiencies 
associated with extant sapphyrins. This is because all sap 
phyrins known at the time of this invention were insoluble 
in aqueous media at or near neutral pH. Thus, the sapphyrins 
known prior to the present invention were incapable of 
forming well characterized, water-soluble complexes with 
phosphorylated entities, including DNA, RNA, nucleotides, 
nucleotide analogues, and simple phosphate and phospho 
nate monoesters, at or near neutral pH. 
In addition, all sapphyrins known at the time of this 
invention were recognized to be quite limited in terms of 
their substitution patterns, bearing only alkyl groups in the 
so-called B-positions. Furthermore, this same lack of sub 
stituent versatility meant that sapphyrin systems carrying 
potentially reactive side chains were completely unknown, 
and this too was recognized as limiting the utility of those 
few sapphyrins known to be extant at the time of this 
invention. Thus, the inventors felt it worthwhile to prepare 
water-soluble sapphyrins. 
Representative examples of alkanes useful as alkyl group 
substituents of water-soluble sapphyrins include methane, 
ethane, straight-chain, branched or cyclic isomers of pro 
pane, butane, pentane, hexane, heptane, Octane, nonane and 
decane, with methane, ethane and propane being preferred. 
Representative examples of aikenes useful as alkenyl group 
substituents include ethene, straight-chain, branched or 
cyclic isomers of propene, butene, pentene, hexene, heptene, 
octene, nonene and decene, with ethene and propene being 
preferred. Representative examples of alkynes useful as 
alkynyl group Substituents include ethyne, Straight-chain, 
branched or cyclic isomers of propyne, butyne, pentyne, 
hexyne, heptyne, octyne, nonyne and decyne, with ethyne 
and propyne being preferred. Representative examples of 
substituted alkyls include alkyls substituted by one or more 
functional groups as described herein. 
Among the halide substituents, chloride, bromide, fluo 
ride and iodide are contemplated in the practice of this 
invention. Representative examples of alkylhalides used in 
5,543,514 
S 
this invention include halides of methane, ethane, propane, 
butane, pentane, hexane, heptane, octane, nonane and 
decane, with halides, preferably chlorides or bromides, of 
methane, ethane and propane being preferred. 
"Hydroxyalkyl” means alkyl groups having hydroxyl 
groups attached. Representative examples of hydroxyalkyls 
include alcohols of methane, ethane, straight-chain, 
branched or cyclic isomers of propane, butane, pentane, 
hexane, heptane, octane, nonane and decane, with alcohols 
of methane, ethane or propane being preferred. "Hydroxy 
alkyl" is meant to include glycols and polyglycols; diols of 
ethane, straight-chain, branched or cyclic isomers of pro 
pane, butane, pentane, hexane, heptane, octane, nonane and 
decane, with diols of ethane or propane being preferred; 
polyethylene glycol, polypropylene glycol and polybutylene 
glycol as well as polyalkylene glycols containing combina 
tions of ethylene, propylene and butylene. 
"Oxyalkyl” means alkyl groups attached to an oxygen. 
Representative examples of oxyalkyls include the alkyl 
groups as herein described having ether linkages. The num 
ber of repeating oxyalkyls within a substituent may be up to 
100, preferably is from 1-10, and more preferably, is 2-3. A 
preferred oxyalkyl is O(CH2CH2O), CH, where x=1-100, 
preferably 1-10, and more preferably, 2-3. "Oxyhydroxy 
alkyl' means alkyl groups having ether or ester linkages, 
hydroxyl groups, substituted hydroxyl groups, carboxyl 
groups, substituted carboxyl groups or the like. 
Representative examples of thioalkyls include thiols of 
ethane, thiols of straight-chain, branched or cyclic isomers 
of propane, butane, pentane, hexane, heptane, octane, 
nonane and decane, with thiols of ethane (ethanethiol, 
CHSH) or propane (propanethiol, CH,SH) being pre 
ferred. Sulfate substituted alkyls include alkyls as described 
above substituted by one or more sulfate groups, a repre 
sentative example of which is diethyl sulfate ((CH3)2SO). 
Representative examples of phosphates include phosphate 
or polyphosphate groups. Representative examples of phos 
phate substituted alkyls include alkyls as described above 
substituted by one or more phosphate or polyphosphate 
groups. Representative examples of phosphonate substituted 
alkyls include alkyls as described above substituted by one 
or more phosphonate groups. 
Representative examples of carboxy groups include car 
boxylic acids of the alkyls described above as well as aryl 
carboxylic acids such as benzoic acid. Representative 
examples of carboxyamides include primary carboxyamides 
(CONH), secondary (CONHR) and tertiary (CONRR") 
carboxyamides where each of R and R" is a functional 
group as described herein. 
Representative examples of useful amines include a pri 
mary, secondary or tertiary amine of an alkyl as described 
hereinabove. Hydroxyalkylamido refers to a substituent 
having a hydroxyalkyl and an amine group; the amine may 
be primary, secondary or tertiary. 
Saccharide includes oxidized, reduced or substituted sac 
charides, including those of Table 1, for example, deriva 
tives such as acetals, amines, and phosphorylated Sugars, 
oligosaccharides, as well as open chain forms of various 
sugars, and the like. Examples of amine-derivatized Sugars 
are galactosamine, glucosamine, sialic acid and D-glucan 
ine derivatives such as 1-amino-1-deoxysorbitol. The sac 
charides employed may be either D or L forms and may also 
be either o. or B forms. The use of modified saccharides is 
also envisioned, such as those including, for example, phos 
phate, methyl or amino groups. It is contemplated that 














include, for example, glucose, glucosamine, galactose, 
galactosamine and mannose. 
TABLE 1 











Galactose Sialic Acid 
Talose Chitosan 






“Carboxyamidealkyl' means alkyl groups with carboxya 
mide groups, optionally having secondary or tertiary amide 
linkages, or amide substituted ethers, ester linkages, tertiary 
amide linkages removed from the ether or the like. Car 
boxyalkyl means alkyl groups having carboxyl groups. 
For the sapphyrins of the present invention, oxyhydroxy 
alkyl may be alkyl having independently hydroxy substitu 
ents and ether branches or may be CH2--1-2OO, or 
OCH22O,O, where n is a positive integer from 1 
to 10, x is zero or a positive integer less than or equal to n, 
and y is zero or a positive integer less than or equal to 
((2n+1)-2x). 
The oxyhydroxyalkyl or saccharide may be CH2 
aO.R., OCH2--OR or (CH2)COR" where n is 
a positive integer from 1 to 10, y is zero or a positive integer 
less than ((2n+1)-q), q is zero or a positive integer less than 
or equal to 2n+1, R" is independently. H, alkyl, hydroxy 
alkyl, Saccharide, Con-Hicom 1-2O, O, O2CCon 
w)Hon-1-2.O.O. or N(R)OCCon-H(2m+1)-2O, O, 
where m is a positive integer from 1 to 10, w is zero or a 
positive integer less than or equal to m, Z is Zero or a positive 
integer less than or equal to ((2m+1)-2w), R is H, alkyl 
hydroxyalkyl or C.Hon.--O.R. where m is a positive 
integer from 1 to 10, Z is zero or a positive integer less than 
((2m+1)-r), r is zero or a positive integer less than or equal 
to 2m+1, and R is independently H, alkyl, hydroxyalkyl, or 
saccharide. 
Carboxyamidealkyl may be alkyl having secondary or 
tertiary amide linkages O (CH),CONHR, 
O(CH),CONHR, (CH2)CONCR), Or 
O(CH2)CONCR), where n is a positive integer from 1 to 
10, R is independently H, alkyl, hydroxyalkyl, saccharide, 
Con-whic(2n+1)-2wo,0- O2CCon-w)Hom--1-2)ow0. Or 
N(R)OCCH21-20O., where m is a positive 
integer from 1 to 10, w is zero or a positive integer less than 
or equal to m, Z is zero or a positive integer less than or equal 
to ((2m+1)-2w), R is H, alkyl, hydroxyalkyl or CH2. 
1)-OR, where m is a positive integer from 1 to 10, Z is 
zero or a positive integer less than ((2m+1)-r), r is zero or 
a positive integer less than or equal to 2m+1, and R is 
independently H, alkyl, hydroxyalkyl, or saccharide. 
The carboxyalkyl may be alkyl having a carboxyl substi 
tuted ether, an amide substituted ether or a tertiary amide 
removed from an ether or CH2O,R or OCH2 
1-OR where n is a positive integer from 1 to 10; y is 
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Zero or a positive integer less than ((2n+1)-q), q is Zero or 
a positive integer less than or equal to 2n+1, R is 
(CH2)COR, (CH),CONHR or (CH2)CONCR), where 
n is a positive integer from 1 to 10; R is independently H, 
alkyl, hydroxyalkyl, saccharide, Co-Ho-2O, O, 
O2CCo-Hom:1-2O.O. Or N(R)OCC Hocanti 
2w)O.O., where m is a positive integer from 1 to 10, w is 
Zero or a positive integer less than or equal to m, Z is zero 
or a positive integer less than or equal to ((2m+1)-2w), R is 
H, alkyl, hydroxyalkyl, or CH2 OR, where m is a 
positive integer from 1 to 10, Z is zero or a positive integer 
less than ((2m+1)-r), r is zero or a positive integer less than 
or equal to 2m+1, and R is independently H, alkyl, 
hydroxyalkyl, or saccharide. 
“Water-soluble' sapphyrins means sapphyrins that are 
soluble in aqueous fluids to about 1 mM or better. Water 
soluble sapphyrins may retain lipophilicity. "Retaining lipo 
philicity' means having greater affinity for lipid-rich tissues 
or materials than surrounding nonlipid-rich tissues or mate 
rials and, in the case of viruses in suspension, the term 
means having affinity for the membranous coat of the virus. 
"Lipid-rich' means having a greater amount of triglyceride, 
cholesterol, fatty acids or the like. 
Generally speaking, the water-soluble sapphyrin deriva 
tives of this invention will include at least one, two or three 






different polyhydroxy groups, or a single sugar residue. 
These groups include a variety of distinct molecules, such 
as, for example, the compounds represented by compounds 
A1-A27 in Table 2 and B1-B8 in Table 3, or substituted 
derivatives thereof. 
Water-soluble sapphyrin derivatives may be based on one, 
two, or more (poly)hydroxyalkylamido units attached to the 
macrocyclic periphery or, alternatively, be based on the 
attachment of one, two, or more hydroxyalkyl groups to the 
macrocycle, the hydroxyalkyl groups including from one to 
six hydroxy moieties or, alternatively, be based on the 
attachment of saccharide or derivatized saccharide moieties 
to the macrocycle. It will be understood that a wide variety 
of different, and yet analogous, substituted derivatives may 
be prepared in accordance herewith. Water-soluble sapphy 
rins may be prepared from an activated form of a sapphyrin 
acid (acid chloride, mixed anhydride, O-acylurea derivative, 
N-acylimidazole) and polyhydroxyamines. 
Preferred substituent groups for R, R-R" and R of 
sapphyrins are listed in Tables 2 and 3. Preferred water 
soluble sapphyrins are listed as compounds A1-A27 of 










Cpd. R2 R R7 R9 
B1 CHOHCHOH O(CHCHO)CH O(CHCHO)CH CHOHCHOH 
B2 CHCHOH CHCHCOOCHCH-OH CHCHCOOCHCHOH CHCH-OH 
B3 CHCH-OH CHCHOH CHCH-OH CHCH-OH 
B4 CHCH-OH CHCHOH CH,CHCOOH CHCHOH 
B5 CHCH-OH CHCHCHOPO(OH) CHCH-OH CHCH-OH 
B6 CHCH CHCONHCH(CHOH),CHOH CHCHCOOH CHCH 
B7 CHCH CHCONHCH(CHOH),CHOH CHNHC(O)CHBr CHCH 
B8 CHCH CHCONHCH (CHOH),CHOH CHOC(O)CHBr CHCH 
The synthesis of representative compounds A21 and A22 30 and alveolar macrophage, glycosylated ara-C for ovarian 
involve compounds that are connected via glycoside bonds cancer cells and lectins for lymphocytes. The synthesis and 
and are obtained starting from dihydroxysapphyrin and use of these and other related systems are thus considered to 
Ol-D-acetobromoglucose as precursors, and using silver tri- fall within the scope of the present invention. 
flate in dichloromethane to effect coupling; or, a trichloro- For the above-described uses, water-soluble sapphyrins 
acetimidate method can be used to effect this coupling'. 35 are provided as pharmaceutical preparations. A pharmaceu 
Other substituents are connected via amide bonds. These tical preparation of a sapphyrin may be administered alone 
later materials are obtained starting from sapphyrin (bis)acid or in combination with pharmaceutically acceptable carriers, 
chloride and 1,3,4,6-tetra-O-acetyl-2-amino-2-deoxy-O-D- in either single or multiple doses. Suitable pharmaceutical 
glucopyranose (tetraacetyl-D-glucosamine). After removing carriers include inert solid diluents or fillers, sterile aqueous 
the protecting groups from the sugar moieties, the desired to solution and various organic solvents. The pharmaceutical 
water-soluble sapphyrin derivatives are obtained. compositions formed by combining a water-soluble sapphy 
The efficiency of compounds A21c and A22b for singlet rin of the present invention and the pharmaceutically accept 
oxygen generation was found to be 11% (in comparison with able carriers are then easily administered in a variety of 
ZnTPPS)'. These water-soluble sapphyrins A21c and dosage forms such as injectable solutions. 
A22b thus have utility as a cellular targeting agent. As is 45 For parenteral administration, solutions of the sapphyrin 
generally known, glycoconjugates have important roles in in sesame or peanut oil, aqueous propylene glycol, or in 
the control of cell division and intercellular association. sterile aqueous solution may be employed. Such aqueous 
Changes in the biochemical and organizational structures solutions should be suitably buffered if necessary and the 
occur during malignant transformation'. Therefore, it may liquid diluent first rendered isotonic with sufficient saline or 
be therapeutically advantageous to alter or inhibit the bio- 50 glucose. These particular aqueous solutions are especially 
synthesis of these tumor cell surface constituents. This might suitable for intravenous, intramuscular, subcutaneous and 
result in tumor cell death caused by the inhibition of the intraperitoneal administration. In this connection, sterile 
biosynthesis of vital membrane components. In this regard, aqueous media which can be employed will be known to 
D-glucosamine derivatives have been proven to be efficient those of skill in the art in light of the present disclosure. 
inhibitors of tumor growth'. 55 The pharmaceutical forms suitable for injectable use 
It is envisioned that differential tumor toxicity and spe- include sterile aqueous solutions or dispersions and sterile 
cific organ targeting can be achieved with different sapphy- powders for the extemporaneous preparation of sterile 
rin saccharide derivatives. For instance, modified sugars injectable solutions or dispersions. In all cases the form must 
such as e.g., Glc-NAc can be included within the scope of be sterile and must be fluid to the extent that easy use with 
substituents that can be appended to the sapphyrin core. All 60 a syringe exists. It must be stable under the conditions of 
that would be needed is to start with an activated sapphyrin manufacture and storage and must be preserved against the 
and 2-acetamido-2-deoxy-3,4,6-tri-O-acetyl-B-D-glucopy- contaminating action of microorganisms, such as bacteria 
ranosylamine. Similarly, other saccharides having cell or and fungi. The carrier can be a solvent or dispersion medium 
tissue specific receptors may be appended to sapphyrins for containing, for example, water, ethanol, polyol (for example, 
molecular targeting. Examples include galactose for binding 65 glycerol, propylene glycol, and liquid polyethylene glycol, 
to the asialoglycoprotein receptor on hepatocytes for target 
ing liver, mannose or fucose for receptors on bone marrow 
and the like), suitable mixtures thereof, and vegetable oils. 
The proper fluidity can be maintained, for example, by the 
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use of a coating, such as lecithin, by the maintenance of the 
required particle size in the case of dispersion and by the use 
of surfactants. The prevention of the action of microorgan 
isms can be brought about by various antibacterial and 
antifungal agents, for example, parabens, chlorobutanol, 
phenol, sorbic acid, thimerosal, and the like. In many cases, 
it will be preferable to include isotonic agents, for example, 
sugars such as mannitol or dextrose or sodium chloride. A 
more preferable isotonic agent is a mannitol solution of 
about 2-8% concentration, and, most preferably, of about 
5% concentration. Prolonged absorption of the injectable 
compositions can be brought about by the use in the com 
positions of agents delaying absorption, for example, alu 
minum monostearate and gelatin. 
Sterile injectable solutions are prepared by incorporating 
the active compounds in the required amount in the appro 
priate solvent with various of the other ingredients enumer 
ated above, as required, followed by filtered sterilization. 
Generally, dispersions are prepared by incorporating the 
various sterilized active ingredients into a sterile vehicle 
which contains the basic dispersion medium and the 
required other ingredients from those enumerated above. In 
the case of sterile powders for the preparation of sterile 
injectable solutions, the preferred methods of preparation 
are vacuum-drying and freeze-drying techniques which 
yield a powder of the active ingredient plus any additional 
desired ingredient from a previously sterile-filtered solution 
thereof. 
As used herein, "pharmaceutically acceptable carrier' 
includes any and all solvents, dispersion media, coatings, 
antibacterial and antifungal agents, isotonic and absorption 
delaying agents and the like that are acceptable for use in the 
human body. The use of such media and agents for phar 
maceutically active substances is well known in the art. 
Except insofar as any conventional media or agent is incom 
patible with the active ingredient, its use in the therapeutic 
compositions is contemplated. Supplementary active ingre 
dients can also be incorporated into the compositions. 
The following examples are included to demonstrate 
preferred embodiments of the invention. It should be appre 
ciated by those of skill in the art that the techniques 
disclosed in the examples which follow represent techniques 
discovered by the inventor to function well in the practice of 
the invention, and thus can be considered to constitute 
preferred modes for its practice. However, those of skill in 
the art should, in light of the present disclosure, appreciate 
that many changes can be made in the specific embodiments 
which are disclosed and still obtain a like or similar result 
without departing from the spirit and scope of the invention. 
For example, other macrocyclic, positively-charged entities 
can be envisioned as binding to phosphate-containing spe 
cies such as nucleotides, oligonucleotides and DNA by 
means of the same or similar oriented electrostatic interac 
tions described herein. 
EXAMPLE 1 
Synthesis of Polyhydroxysapphyrins 
Preparation of 3,12,13.22-tetraethyl-8,17bisdi (hydroxy 
ethyl)aminocarbonylethyl-2,7,18,23-tetramethylsapphyrin, 
A1. Sapphyrin bis acid A19 (synthesized as described in 
references 1, 6 and U.S. Pat. No. 5,302.714 where R (R in 
current scheme) is CHCOOH) (66 mg, 0.1 mmol) was 
dissolved/suspended in dry dichloromethane (30 ml) and 0.5 
ml oxalylchloride and 1 drop of DMF were added. The 














then evaporated to dryness. The resulting sapphyrin bis acid 
chloride was dissolved in dry dichloromethane (20 ml) and 
slowly added under argon to the solution of diethanolamine 
(52.5 mg, 0.5 mmol) in dry dichloromethane (30 ml), which 
contained also 5 mg of 4-dimethylaminopyridine and 0.2 ml 
pyridine. The reaction mixture was stirred at room tempera 
ture for 24 hours and then washed with brine, which 
contained 5% hydrochloric acid. The water phase was 
washed 3 times with dichloromethane containing 20% 
methanol. The combined organic extracts were dried over 
sodium sulfate and evaporated. Crystallization from etha 
nolhexane (1:3) gave 75 mg (86.9%) of product A1. 
H NMR (300 MHz, CDC) 8:-5.13 (2H, s, NH), -4.95 
(1H, s, NH), -4.78 (2H, s, NH), 2.18 (4H, t, CHCH), 2.20 
(4H, t, CHCH), 2.24 (4H, t, CHCH), 2.88 (8H, t, 
NCHCHOH), 2.94 (8H, t, NCHCH-OH), 3.56 (4H, t, 
CHCHCON), 4.07 (6H, s, CH), 4.25 (6H, s, CH), 4.49 
(2H, q, CHCH), 4.52 (2H, q, CHCH), 4.79 (2H, q, 
CHCH), 5.15 (2H, q, CHCH), 5.30 (4H, t, 
CHCHCON), 6.05 (4H, brs, OH), 11.66 (2H, s, meso-H), 
11.78 (2H, s, meso-H). FAB MSm/e (rel. intensity) 863 (98, 
MH"),864 (78, MH"),862 (56,M). HRMS Calcd for 
CHNO:862.520676. Found 862.523102 UV/VIS 
(HO): A 410.5, 621.0, 672.0. 
Preparation of 3,12,13.22-tetraethyl-8,17-bis(tris 
(hydroxymethyl)methylaminol-carbonylethyl-2,7,18,23 
tetramethylsapphyrin, A3. Sapphyrin bis acid structure A19 
(66 mg, 0.1 mmol) was dissolved in dry tetrahydrofuran (20 
ml) and 1,1'-carbonyldiimidazole (33 mg, 0.2 mmol) was 
added and the solution was stirred at room temperature for 
1 hour. A solution of tris(hydroxymethyl)aminomethane 
(24.2 mg, 0.2 mmol) in 3 ml of water was added. The 
reaction mixture was stirred for 12 hours and the imidazole 
was filtered off; the solvent was evaporated in vacuo and the 
product crystallized from a mixture of methanol-dichlo 
romethane (1:10). The yield of product A3 was 73 mg 
(81.5%). FAB MS m/e (rel. intensity) 896 (100,MI"), 897 
(60, MH"). HRMS: Calcd. CHNOs 895.52072. Found 
895.52099. UV/VIS (HO): 412,622,673. 
EXAMPLE 2 
Synthesis of Sapphyrin Diglycosides 
Sapphyrin mono- and diglycosides were prepared by the 
glycosylation of sapphyrin alcohols with O-D-acetobromo 
glucose and O-D-acetobromogalactose with a silver catalyst. 
The most advantageous catalyst was found to be silver 
triflate, although silver tetrafluoroborate and silver carbonate 
also gave very good results. With polyalcohols it is possible 
to determine the conversion to glycosides by the molar ratio 
alcohol-halogenose/silver catalyst. The inventors were able 
to introduce 1 or 2 sugar units as a function of the molar ratio 
of hydroxy groups/halogenose/silver catalyst. The trichlo 
roacetimidate method can also be used to effect the coupling 
of a sapphyrin and a glycoside.' 
Preparation of 3,12,13,22-Tetraethyl-8,17-di(hydroxypro 
pyl)-2,7,18,23-tetramethylsapphyrin A2. In accordance with 
the general optimized procedure for the production of sub 
stituted sapphyrins", 4,4'-diethyl-5,5-diformyl-3,3'-dim 
ethyl-2,2'-bipyrrole (544 mg, 2.0 mmol) and 2,5-bis(5-car 
boxy-3-hydroxypropyl-4-methylpyrrol-2-ylmethyl)-3,4- 
diethylpyrrole (1.028 g, 2.0 mmol) were dissolved in 
absolute ethanol (2.0 l) under heating. The reaction mixture 
was allowed to cool to room temperature and p-toluene 
sulfonic acid monohydrate (1.5 g) was added. Air was 
vigorously bubbled through the reaction mixture for 4 days. 
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The ethanol solvent was then removed using a rotorary 
evaporator and the product isolated by column chromatog 
raphy on silica gel using dichloromethane containing metha 
nol (1-5%) as the eluent. The bis hydrochloride salt was 
prepared by washing a dichloromethane solution of this 
sapphyrin with 1N HCl to give a 78% (1.151 g) yield of the 
diprotonated product. H NMR for A2-2HCl (300 MHz, 
CDC1): 8-493 (2H, s, NH), -4.63 (1H, s, NH), -4.30 (2H, 
s, NH), 2.07 (6H, t, CHCH), 2.16 (6H, t, CHCH), 2.76 
(4H, pentet, CHCHCH-OH), 4.03 (6H, s, CH), 4.06 (4H, 
t, CHCHCH-OH), 4.20 (6H, s, CH), 4.59 (4H, q, 
CHCH), 4.68 (4H, q, CHCH), 4.77 (4H, t, 
CHCHCH-OH), 11.59 (2H, s, meso-H), 11.66 (2H, s, 
meso-H); C NMR (80 MHz, CDC1): 8 13.15, 16.19, 
17.84, 1914, 21.85, 21.94, 25.04, 36.94, 62.25, 91.17, 
97.53, 127.30, 128.38, 128.77, 131.77, 133.65, 13446, 
138.63, 140.54, 142.26, 143.88; UV-Vis (free base in 
MeOH): A (e) 443 (230 000), 573 (1800), 618 (6 400), 
669 (6 800) HRMS FAB calcd for C.H.N.O. (MH") 
660.427751, obsd 660.428736; Anal. Calcd for 
CHNOCl.HO: C, 67.19; H, 7.65; N, 9.33; Cl, 9.44. 
Found: C, 67.25; H, 7.61; N, 9.41; Cl, 9.35. 
Preparation of 8,17-di(tetraacetate-O,3-D-glucopyranox 
ypropyl)-3,12,13,22-tetraethyl-2,7,18,23-tetramethylsap 
phyrin, A21b. 3,12,13.22-Tetraethyl-2,7,18,23-tetramethyl 
8,17-di(hydroxypropyl) sapphyrin A2 (132 mg, 0.2 mmol) 
was dried with silver triflate (0.2569 g, 1 mmol) and barium 
carbonate (0.5 g) for 2 hours at 20°C/1.32 mm Hg in an 
apparatus equipped with a septum. The apparatus was 
flushed with argon (2x) and dry dichloromethane (50 ml) 
was added through the septum. After dissolution, the mix 
ture was cooled to -45° C. and a solution of O-D-glucopy 
ranosylbromide tetraacetate (0.411 g 1 mmol) in dichlo 
romethane (20 ml) was gradually added through septum 
under stirring. The reaction mixture was stirred at -45° C. 
for 1 hour, then allowed to warm to room temperature with 
exclusion of light and stirred for 8 hours. The reaction 
mixture was diluted with 50 ml of dichloromethane, and 
filtered with celite; the filtrate was washed with a saturated 
solution of sodium hydrogen carbonate and water, dried over 
sodium sulfate and the solvent was evaporated. Pure product 
was obtained by column chromatography on silica gel with 
dichloromethane with 4% of methanol as a eluent. The yield 
of product A21b was 250 mg (94.7%). H NMR spectrum 
(300 MHz, CDC1): 8-6.21-6.07, -5.81, -5.75, 2.03, 2.05, 
2.11, 2, 3, 2.16, 2.28, 2.31, 3.09, 4.11, 4.17, 4.24, 4.33, 4.51, 
4.53, 4.72, 4.74, 5.29, 11.59, 11.66. FAB MS, m/e (rel. 
intensity): 1321 (90, MH)), 1322 (56, MH"), 1320 (45, 
MI). HRMS Calcd. for CHNO 1319.6100. Found 
1320.617916 (MHI). 
The same experimental procedure was used for the prepa 
ration of tetraacetylgalactose and tetraacetylmannose sub 
stituted sapphyrins. In these cases, the sugar unit was varied 
using the same protecting group. 
Preparation of 8,17-di(tetrabenzoate-O,3-D-glucopyran 
oxypropyl)-3,12,13,22-tetraethyl-2,7,18,23-tetramethylsap 
phyrin, A21a. The same procedure as for tetraacetylderiva 
tive with ol-D-glucopyranosylbromide tetrabenzoate (0.660 
g, 1 mmol) gave product A21a in 97.6% yield. FAB MS m/e 
(rel. intensity): 1817 (95, MH"), 1818 (67, MH"), 1816 
(62, MI). HRMS Calcd. for CHNO 1815.7346. 
Found 1816.743117 (IMH)). 
Preparation of 8,17-di(O.B-D-glucopyranoxypropyl)3,12, 
13,22-tetraethyl-2,7,18,23-tetramethylsapphyrin, A21c. The 
product was prepared from protected derivatives (acetyl, 
benzoyl) by removal of the protecting group in methanol 













hydroxide, or potassium cyanide. Pure product was obtained 
by crystallization, or reverse phase chromatography (C8 
modified silica gel) with methanol as a eluent. The yield of 
product A21c was 67%. FAB MS m/e (rel. intensity):986 
(70, MI), 987 (56, MH"). HRMS Calcd, for 
C.H.N.O. 985.54108. Found 985.5417. Elemental 
analysis: calc. 65.77% C, 7.67% H, 7.10% N; found 65.65% 
C, 7.69%H, 7.04%N. UV/VIS (HO): 416,597.5, 642, 
712; (MeOH): 445. 
EXAMPLE 3 
Synthesis of Sapphyrin Bis(glycosamides) 
Sapphyrin bis(glycosamides) were prepared by conden 
sation of an activated form of the above-described sapphyrin 
acid (acid chloride, mixed anhydride, O-acylurea, 
N-acylimidazole derivative) with free, or O-acetylated gly 
coamines (2-amino-2-deoxy-glucopyranose, mannopyra 
nose, galactopyranose). 
Preparation of 3,12,13.22-Tetraethyl-8, 17-bis(1,3,4,6- 
tetra-O-acetyl-2-amino-2-deoxy-o,-D-glucopyranose)- 
carbonylethyl)-2,7,18,23-tetramethylsapphyrin A22a, Sap 
phyrin bis acid structure A19 (69 mg, 0.1 mmol) was 
converted to bis acid chloride as previously described. Bis 
acid chloride was dissolved in dry dichloromethane under 
argon and was slowly added to a solution of 1,3,4,6-tetra 
O-acetyl-2-amino-2-desoxy-O-D-glucopyranose (0.1736, 
0.5 mmol) in dichloromethane, which also contained 10 mg 
of 4-dimethylaminopyridine and 0.5 ml of dry pyridine at 
room temperature. The reaction mixture was stirred for 14 
hours, then washed with water, the organic layer was evapo 
rated and the product obtained by column chromatography 
on silica gel with dichloromethane containing 2-10% 
methanol as an eluent. The yield of product A22a was 114.6 
mg (85.0%). "H NMR spectrum (300 MHz, CDCl): 
8=-4.91, -4.59, 1.94, 2.06, 2.12, 2.27, 3.41, 3.689, 3.84, 
3.91, 3.93, 4.05, 4.12, 4.22, 4.54, 4.63, 4.72, 5.04, 5.19, 5.22, 
11.59, 11.69. FAB MS, m/e (rel. intensity): 1347 (96, M'), 
1348 (84, MH"). HRMS: Calcd. CHN.O. 
1347,61428. Found 347.61624. 
Preparation of 3,12,13,22-Tetraethyl-8,17-bis(2-amino 
2-deoxy-O,3-D-glucopyranose)-carbonyethyl)-2,7,18,23 
tetramethylsapphyrin, A22b. The above-described acety 
lated sapphyrin derivative A22a (13.4 mg, 0.01 mmol) was 
dissolved in methanol (10 ml) and a solution of 3 mg KOH 
in methanol was added. The reaction mixture was stirred for 
4 hours and then the pH adjusted to 6 by adding hydrochloric 
acid. After evaporating to dryness, the product was crystal 
lized from methanol-dichloromethane (1:1), or obtained by 
reverse phase chromatography with methanol as eluent. The 
yield of product A22b was 10.38 mg (88.0%). FABMS, mile 
(rel. intensity): 1012 (76, MH"), 1011 (54, MI). UV/VIS 
(HO): A 413,621,671. 
Deacetylation could also be achieved under basic condi 
tions by using, e.g., NH in methanol, sodium methoxide in 
methanol, DABCO in methanol, or KCN in methanol, each 
with good yields. 
EXAMPLE 4 
Synthesis of Mono- and Bis-saccharide-Substituted 
Sapphyrins 
In general, saccharide-substituted sapphyrins were pre 
pared by the reaction of an activated sapphyrin mono- or 
bis-acid and a polyhydroxy-amino component. 
5,543,514 
23 
Preparation of 3,8,17.22-tetraethyl-12-(carboxyethyl)-2, 
7,13,18,23-pentamethylsapphyrin A23a. Part a: Preparation 
of 3,8,1722-tetraethyl-12-(methoxycarbonylethyl)-2,7,13, 
18,23-pentamethylsapphyrin. In accordance with the general 
optimized procedure for the production of substituted 
sapphyrins', 4,4'-diethyl-5,5-diformyl-3,3'-dimethyl-2,2'- 
bipyrrole (272 mg, 1.0 mmol) and 2,5-bis(5-carboxy-3- 
ethyl-4-methylpyrrol-2-ylmethyl)-3-methoxycarbonylethyl 
4-methylpyrrole (523 mg, 1.0 mmol) were condensed to 
give sapphyrin A23a in 75.4% yield (0.490 g). H NMR 
(300 MHz, CDC1): 8–4.78 (1H, s, NH), -4.76 (1H, s, NH), 
-4.32 (1H, s, NH), -4.13 (2H, s, NH), 2.35-2.43 (12H, m, 
CHCH), 3.85 (2H, t, CHCH2COCH), 3.99 (3H, s, 
CH), 4.29 (6H, s, CH), 4.38 (3H, s, CH), 4.44 (3H, s, 
CH) 4.67-4.74 (8H, m, CHCH), 5.22 (2H, t, C 
HCHCOCH), 11.82 (1H, s, meso-H), 11.85 (1H, s 
meso-H), 11.88 (2H, s, meso-H). ''C NMR (75 MHz, 
CDC1): 8-12.7, 13.1, 15.9, 17.8, 17.9, 21.0, 23.0, 37.1, 
52.1, 91.5, 92.0, 98.3, 98.4, 126.9, 127.0, 129.5, 129.6, 
130.2, 132.7, 132.8, 134.7, 135.3, 135.5, 136.6, 136.7, 
137.7, 139.1, 141.5, 141.7, 173.3. HRMS: Calcd. for 
CHNO: 643.3886. Found 643.3887. 
Part b: preparation of sapphyrin acid A23a. A ca. 1:1 V.V. 
mixture of trifluoroacetic acid and conc. hydrochloric acid 
(10 ml for 100 mg of starting sapphyrin) was used to 
hydrolyze the ester. The reaction was run at 50° C. for 2 days 
after which time the desired sapphyrin acid product was 
obtained as its bis HCl adduct. After drying in vacuo, this 
protonated product was purified by column chromatography 
on silica gel (methanol 5% in dichloromethane, eluent). The 
yield was ca. 95%. H NMR (300 MHz, CDCl): 8=-5.84 
(2H, bs, NH), -5.35 (3H, bs, NH), 2.20 (12H, t, C 
HCH), 3.23 (2H, t, CHCHCO2H), 4.03 (3H, s, CH), 
4.15 (6H, s, CH,), 4.23 (3H, s, CH), 4.41 (3H, s, CH), 4.65 
(4H, q, CHCH), 4.74 (4H, q, CHCH), 4.79 (2H, m, C 
HCHCO2H), 11.42 (2H, s, meso-H), 11.55 (1H, s, meso 
H), 11.58 (1H, s, meso-H). C NMR (75 MHz, CDCl): 
8-12.7, 12.9, 14.3, 15.9, 17.7, 17.9, 20.6, 20.9, 22.8, 36.5, 
36.7, 61.9, 91.6, 98.1, 120.7, 120.9, 125.4, 125.4, 127.3, 
129.1, 129.2, 130.0, 132.7, 132.8, 1348, 134.9, 35.2, 
135.4, 135.6, 135.7, 136.1, 136.8, 136.9, 137.0, 137.7, 
139.31, 1414, 1418, 1418, 1744. FAB MS, m/e (rel 
intensity): 631 (48, M+2H]"), 630(100, M+H"), 629 (52, 
M"); HRMS: Calcd. for CHNO: 629.3730. Found 630. 
3798 M+H"; for CHNO, M+H": calcd. 630.3808. 
Reaction of the sapphyrin monoacid, 3,8, 17,22-tetraethyl 
12-(carboxyethyl)-2,7,13,18,23-pentamethyisapphyrin 
(A23a) with 2-deoxy-2-aminopyranosides: For these kinds 
of products, the above named sapphyrin monoacid was 
activated (via conversion to its acid chloride, a carbodiimide 
derivative, an NHS ester, or mixed anhydride) and reacted 
with the chosen amino-saccharide derivative (or a protected 
form thereof) to give the corresponding sapphyrin glycosa 
mides. 
3,8,17.22-Tetraethyl-12-(2-amido-2-deoxy-O,3-D-galac 
topyranose)-ethyl-2,7,13,18-pentamethylsapphyrin Ib. Sap 
phyrin monoacid A23a (3,8,17.22-tetraethyl-12-(carboxy 
ethyl)-2,7,13,18,23-pentamethylsapphyrin) (63 mg, 0.1 
mmol) was dissolved in 5 ml of dry DMF. Then, 1,1'- 
carbonyldiimidazole was added (32 mg, 0.2 mmol) and the 
reaction mixture stirred at room temperature for 2 hours. A 
solution of D-galactosamine-HCl in 3 ml of water contain 
ing 0.3 ml of pyridine was then slowly added. The resulting 
reaction mixture was stirred for 2 days before being worked 
up in accord with the following procedure: Sodium bicar 
bonate (5 ml of a saturated aqueous solution) was first 














(A23b) was filtered off, washed with cold water (3 ml) and 
dried. 
The same procedure as described above could also be 
used for the preparation of A23c-A23e when D-glu 
cosamine.HCl, D-mannosamine.HCl and L-mannosamine 
.HCl were used as alternative sugar moiety sources. Alter 
natively, substituted systems derived from 2-amino-2- 
deoxy-O-D-glucopyranose residue could be prepared via the 
use of 1,2,3,4-tetra-O-acetyl-2-amino-2-deoxy-O-D-glu 
copyranose hydrobromide (ref. S. Hanessian: Methods in 
Carbohydrate Chemistry, Vol. 6, 208) in the key coupling 
step. In addition, as another kind of variant, EDC, diisopro 
pylcarbodiimide, or NHS ester activation could be employed 
to achieve the critical sapphyrin acid activation process. In 
all cases, the crude sapphyrin glucosamides were obtained in 
65–75% yield and were purified via reverse column chro 
matography or via conversion (when necessary) to the 
corresponding 1,2,3,4-tetra-O-acetyl derivatives and purifi 
cation as such. In these latter instances, acetylation was 
effected using acetic anhydride in pyridine and chromatog 
raphy was carried out on silica gel using methanol 2% in 
dichloromethane as the eluent. Removal of the acetyl groups 
was then effected using either acid catalysis (trace of HCl) 
or basis hydrolysis (KOH in methanol for 6 hours). 
Characterization data for the exemplary compound, 3,8, 
17,22-tetraethyl-12-(2-amido-2-deoxy-O,3-D-galactopyra 
nose)-ethyl-2,7,13,18-pentamethylsapphyrin (A23b): FAB 
HRMS: Calcd for CHNO (M+H"): 791449604; 
found: 791.457003. Anal.: Calcd. for CHNO (791.01): 
69.85% C, 7.39% H, 10.62% N; found. 69.60% C, 7.45% H, 
10.49% N. 








A23c: X= HO 









A23d; X = HO 




A23e:X= O NH 
Man HO OH 
OH 
A strategy analogous to that given above (i.e., activation 
with 1.1 mol. eq. of a dehydrating reagent such as EDC, 
diisopropylcarbodiimide or 1,1'-carbonyl-diimidazole; and 
then coupling with 1.1 molar eq. of the aminocomponent) 
could also be used for the preparation of glycosamide 
derivatives of either the sapphyrin bisacid, 3,12,13,22-tet 
raethyl-8, 17-bis(carboxyethyl)-2,7,18,23-tetramethylsap 
phyrin A19, or its monoester, monoacid analogue A24, 
3,12,13,22-tetraethyl-8-(carboxyethyl)-17-(methoxycarbon 
ylethyl)-2,7,18,23-tetramethylsapphyrin. In the latter case, 
deprotective removal of the methyl ester could be effected 
using a 1:1 mixture of HCl and TFA at 50° C. for 4 hours. 
This provides a precursor compound for sapphyrin-saccha 
ride derivatives having structures A6, A7 and A26. Structure 
A7 with the sugar hydroxyls blocked with acetyls or other 
protecting R groups, provides a convenient starting material 
for the ligative coupling with an amine-containing compo 
nent and, as a result of this, is extremely useful for the 
synthesis of unsymmetrical water soluble sapphyrins. 
A19: R* = CHCHCOOH, R = CHCHCOOH 
A24; R = CHCHCOOH, R = CHCHCOOCH 
























A6: R7= CH2CH3CONH 
A7: R7 - CHCHCOOH 
A26: R7 = CHCH,COOCH 
The R groups on the saccharide moiety may be hydrogen, 
alkyl, aryl or acyl. Preferably, R is methyl, acetyl, benzyl, or 
trimethylsilyl. 
EXAMPLE 5 
Preparation of Sapphyrin Gluconamides 
In general, the activated sapphyrin mono-(A23a) and bis 
acids (A19, A25) described in Example 4 were reacted with 
1-amino-1-deoxy-D-sorbitol (or, in general, any D-glucam 
ine in DMF-water (or aqueous buffer, pH 7.5-9) mixtures to 
give the sapphyrin gluconamides. Here, activation was 
effected using carbodiimide derivatives such as EDC or 
1,3-diisopropylcarbodiimide or via the use of mixed anhy 
drides. 
3,12,13.22-Tetraethyl-8, 17-bis(1-amido-1-deoxy-D-glu 
citol)ethyl)-2,7,18,23-tetramethylsapphyrin IVa. 3,12,13,22 
tetraethyl-8, 17-bis(carboxyethyl)-2,7,18,23-tetramethylsap 
phyrin A19 (Example 4) (69 mg, 0.1 mmol) was dissolved 
in dry DMF (5 ml) and cooled to 0° C. EDC (96 mg, 5 
mmol) was then added together with 5 mg of 1-hydroxy 
benzotriazol. The resulting solution was stirred with external 
ice bath cooling for 1 hour. At this juncture, the chosen 
D-glucanine in this case, 1-amino-1-deoxy-D-glucitol; 
alternative name: 1-amino-1-deoxysorbitol) (108.7 mg, 6 
mmol) in water (3 ml) and 4-dimethylaminopyridine (3 mg) 
were slowly added. Following this addition, the reaction 
mixture was stirred with cooling for 1 additional hour before 
being stirred for 3 more days at r.t. Work up consisted of 
adding 3 ml of saturated solution of sodium bicarbonate and 
then filtering of the resulting precipitate 5 minutes later. The 
resulting product A4 was washed with cool water (3 ml) and 
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dried. Yield of A450.9 mg (60.81%). Characterization data: 
FAB HRMS: Calcd for CHNO (IM+H"): 
1014.555197; found 1014.557099. UV-vis : 424.5, 616, 
681, 738 (H.O, pH 2); 400.0, 421.5,556, 623,674 (H.O, pH 
7). 
The same procedure was applied in the case of 3,12,13, 
22-tetraethyl-8,17-bis(carboxymethyl)-2,7,18,23-tetrameth 
ylsapphyrin A25 (Example 4). The resulting product A5, 




This water-soluble product A23f was characterized by 
studying its interactions with DNA in a PIPES buffer at pH 
7. Here, for instance, it was found that the sapphyrin 
substituted chitosan gave a detectable CD spectrum only 
after the addition of DNA. 
A Sapphyrin Substituted Alginic Acid. In this study, 
alginic acid (a mixed polymer of mannuronic and glucuronic 
acid, M-48,000-186,000, n is from about 100 to about 500, 
preferably 300, Fluka, Ronkonkoma, N.Y.) and 3,8,17,22 
EXAMPLE 6 
Preparation of Polysaccharide Substituted 
Sapphyrins 
Sapphyrin Substituted by a Low Molecular Weight Chi 





(poly(1,4-B-D-glucopyranosamine; alternative name: 
2-amino-2-deoxy-(1-4)--D-glucopyranan, Fluka, 
Ronkonkoma, N.Y.; M-70,000, n is from about 200 to 500, 
preferably about 350) was used for coupling and was 
attached to the activated form of the sapphyrin monoacid 
A23a (i.e., 3,8, 17.22-tetraethyl-12-(carboxyethyl)-2,7, 13, 
18,23-pentamethylsapphyrin) via an amide bond. Specifi 
cally, the sapphyrin monoacid (31.5 mg, 0.05 mmol) was 
dissolved in dry DMF (3 ml). After cooling with an external 
ice bath, EDC (50mg) was added. The resulting activation 
process was allowed to proceed for 1 hour. At this juncture, 
a saturated solution of chitosan in TEAB (triethylammonium 
hydrogen carbonate) buffer, pH 8.5 (3 ml) was added. The 
reaction mixture was held for another 1 hour in the external 
ice bath. It was stirred for additional 7 days at r,t., then 
subjected to 1 hour of stirring in an ultrasonic bath. The 
final, resulting reaction mixture was evaporated in vacuo, 










18,23-pentamethylsapphyrin A27d were used as the cou 
pling partners with the key linkage being established again 
via an amide bond. Specifically, a saturated solution of 
alginic acid in a 5 ml water-pyridine mixture (4:1) was 
prepared using an ultrasonic bath. The resulting solution was 
cooled using an external ice bath before EDC (50 mg) was 
added. This activation reaction was kept cool for 1 hour 
before a solution of sapphyrin A27d (10 mg) in DMF (3ml) 
was added. The resulting reaction mixture was first stirred 
with external ice bath cooling for 1 hour and then for 7 days 
at r,t. and then, finally, for 1 hour in an ultrasonic bath. 
Following this, the solvents were removed by evaporation in 
vacuo. The resulting residues were redissolved in water, 
filtered, and then retaken to dryness in vacuo. In this case, 
the product demonstrated a CD spectrum (PIPES buffer, pH 













By use of the above procedure, or modest modifications 
thereof known to one of skill in the art in light of this 
disclosure, it is possible to prepare sapphyrin substituted 
hyaluronic acid derivatives A27b (for the needed precursor, 
see: J. Am. Chen. Soc. 1994, 116, 75.15-7522) or dextran 
substituted sapphyrins A27c (for the needed precursor, see: 
Arch. Biochem. Biophys. 1975, 169, 464–473). 
EXAMPLE 7 
Sapphyrin-DNA Interactions 
The present inventors have discovered that sapphyrin 
binds to double- and single-stranded DNA and RNA, and 
furthermore, that it does so in a novel and unexpected 
C. 
Sapphyrin Binds to DNA: The first evidence for sapphy 
rin DNA binding came from the observation that an excess 
of sapphyrin, which is green in solution, can rapidly and 
specifically precipitate green DNA fibers. The inventors 
propose that this binding and precipitation is due to the 
chelation of the polyanionic sugar phosphate backbone of 
DNA by sapphyrin. This leads to charge neutralization and 
through the resulting hydrophobic effects, the DNA falls out 
of solution. Such precipitation effects have not been reported 
for other DNA binding compounds which are known to 
either intercalate or groove bind with DNA. 
Further evidence that sapphyrin binds to DNA was pro 
vided by CD spectroscopy, a technique that can detect 
chirality. Sapphyrin is an achiral macrocycle that shows no 
significant CD spectra by itself in solution. However, in the 
presence of DNA, a sapphyrin CD spectrum was induced. 
This is consistent with relatively rigid binding to DNA, a 
chiral macromolecule, which places Sapphyrin in a chiral 
environment and yields the observed induced CD effect. 
In addition, UV-visible spectroscopy provides still further 
evidence that sapphyrin binds DNA. Upon addition of a 
large excess of DNA, changes in the visible absorption 
spectrum occur. The Soret-like transition that occurs at 410 
nm is red-shifted by approximately 12 nm. This is taken as 
evidence that DNA is interacting directly with the sapphyrin 
macrocycle. 
Finally, the inventors have determined that sapphyrin 
exhibits enhanced fluorescence in the presence of DNA. 
Sapphyrin alone shows only minimal fluorescence in aque 
ous buffered solution, but has been shown to either dimerize 
or aggregate in polar solvents resulting in a quenching of the 
sapphyrin fluorescence. The fluorescence enhancement 
effect discovered by the inventors is thus considered to be 
the result of binding to DNA which breaks up the dimers/ 
aggregates and creates "monomeric' sapphyrins bound to 
DNA. Using this fluorescence enhancement as measurement 
of binding, the lower limit of the apparent binding constant 














Sapphyrin-DNA Binding is not Intercalation or Groove 
Binding: Unwinding of double helical DNA has traditionally 
been accepted as a signature of DNA intercalators. Based on 
the apparent binding constant obtained using fluorescence 
spectroscopy, the inventors conducted topoisomerase-based 
unwinding studies using concentrations of Sapphyrin where 
the sapphyrin macrocycle was significantly bound to the 
DNA. In such studies, no sapphyrin-mediated DNA unwind 
ing was detected, leading to the conclusion that Sapphyrin 
cannot be intercalating. 
Preliminary results have indicated that nearly identical 
visible absorption changes can be observed when sapphyrin 
is titrated with either double-stranded DNA or single 
stranded DNA. As single-stranded DNA contains no higher 
order structure, such as a major or minor groove, and the 
interaction appears to be spectroscopically identical between 
the two types of DNA, this data demonstrates that sapphyrin 
cannot be groove binding. 
Sapphyrin Binds to the Phosphate Backbone of DNA: 
Recent X-ray crystallographic evidence has shown that the 
sapphyrin macrocycle can bind both monobasic phosphoric 
acid and monobasic phenyl phosphate 13. The inventors 
conducted a study aimed to link this solid state evidence to 
the interaction between sapphyrin and DNA which occurs in 
solution. They found that, in solution, spectroscopic simi 
larities exist between sapphyrin in the presence of DNA and 
sapphyrin in the presence of diethyl phosphate. The latter is 
a simple phosphate that compares with the phosphates used 
in the X-ray crystallographic studies. 
UV-visible spectral shifts comparable to those obtained 
with DNA can be observed when sapphyrin is titrated with 
diethyl phosphate. With diethyl phosphate, the Soret-like 
transition is red-shifted by approximately 9 mm. In addition, 
fluorescence enhancement in the presence of diethyl phos 
phate can be observed as in the case with DNA. The only 
structural similarity between this simple phosphate and the 
DNA is the phosphate anion and, when taken in conjunction 
with the X-ray crystallographic data, these spectroscopic 
techniques provide evidence for the novel mode of DNA 
binding proposed by the present inventors. 
Porphyrins and Sapphyrins Interact Differently with 
DNA: To demonstrate that sapphyrins interact differently 
with DNA than their nearest relatives, porphyrins, the inven 
tors synthesized a porphyrin which was functionalized in a 
similar manner as the sapphyrin A1. Spectroscopically, these 
two molecules act very differently in the presence of DNA. 
Neither an induced CD effect nor any significant shifts in the 
visible absorption spectrum are observed with the function 
alized porphyrin in the presence of DNA. In contrast to the 
fluorescence enhancement of sapphyrin, the porphyrin 
shows a decrease in fluorescence intensity in the presence of 
DNA. 
The novel findings described in this example form the 
basis for even further uses of sapphyrin and sapphyrin 
derivatives as tools in the research or clinical laboratory. A 
particularly important application contemplated by the 
present inventors is to use sapphyrin, or derivatives thereof, 
in recovering DNA samples, for example, after electrophore 
sis. This may be applied as a general technique, or adapted 
for more specific DNA recognition and recovery by employ 
ing functionally derivatized sapphyrins having nucleobase 
specificity. 
EXAMPLE 8 
Photocleavage of pBR322 Plasmid DNA in the 
Presence of Sapphyrin 
Photocleavage of DNA with water-soluble tetrahydrox 
ysapphyrin A1 was monitored using pBR322 plasmid. 
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The irradiated solutions consisted of 100 lull of 0.1 SSC 
buffer (saline sodium citrate: 15 mM NaCl, 1.5 mM sodium 
citrate, pH 7.0) containing 32 uM pBR322 DNA phosphates 
and either 0 or 4 uM sapphyrin. Plasmid pBR322 was 
purchased from Gibco BRL and contained 290% of the 
material as Form I, i.e., supercoiled DNA. The solutions 
were irradiated at room temperature with a high pressure 
Xenon lamp through a pyrex filter to stop UV light of 
wavelengths below about 300 nM. The samples were irra 
diated in a quartz cuvette measuring 1 mm in diameter and 
received approximately 3400 W/m. After irradiation, 3 L 
50% glycerol/water loading buffer containing bromophenol 
blue was added to 9 uL irradiated solution. The samples 
were analyzed on an 0.8% agarose gel containing ethidium 
bromide in Tris-acetate buffer at 90 V for 30 minutes. The 
DNA was detected by fluorescence using a UV lamp. 
Analysis of two control lanes, one in the absence of 
sapphyrin and one in the presence of sapphyrin with no light 
exposure, indicated that >90% of the plasmid DNA was 
Form I DNA, i.e., supercoiled DNA. Analysis of the three 
experimental lanes where sapphyrin was incubated with the 
DNA with light exposure for 10, 20 and 40 minutes indi 
cated that incubation with sapphyrin at 4 uM concentration 
caused photocleavage of Form I DNA to Form II and III 
DNA, i.e., supercoiled DNA was cleaved to form nicked 
DNA having one single strand break and linear DNA having 
a double-strand break. At 40 minutes of light exposure, 
>90% of the plasmid DNA was either Form II (nicked) or 
Form III (linear) DNA. 
These data demonstrate the utility of the herein-described 
sapphyrins for photoinduced cleavage of DNA and for use as 
a photodynamic agent. The ability to further modify sap 
phyrin molecules via appended functional groups and 
thereby fine-tune receptor specificity and localization pro 
vides an advantage of the water-soluble sapphyrins over 
those that are exclusively alkyl substituted. 
EXAMPLE 9 
Water-Soluble Sapphyrins as Therapeutic Agents 
The discoveries embodied by the present invention may 
be advantageously exploited in further scientific research, 
and importantly, in the development of new methods and 
compositions for treating various human diseases including 
cancer. The sapphyrin-saccharide derivatives are envisioned 
to be of use in a wide variety of clinical embodiments, 
especially due to specific cellular targeting from saccharide 













sapphyrins also have potential for use directly as chemo 
therapeutics. 
Sapphyrin may also be used as a delivery agent for the 
intracellular targeting of any drug that has a phosphate 
group. Of course, given the synthetic methodology disclosed 
herein, it is contemplated that the sapphyrin may be deriva 
tized by the introduction of further groups to the periphery 
of the macrocycle, which groups would add the specificity 
and/or selectivity of the sapphyrin-drug interaction. Sapphy 
rin-drug interactions of this sort may be based upon either 
non-covalent interactions, or alternatively, may employ a 
covalent bond that is cleaved on exposure to the intracellular 
environment. 
The newly-discovered interaction between sapphyrin and 
DNA, in which sapphyrin acts as a chelate for the phosphate 
backbone of DNA, is particularly important. The binding 
constant of unmodified sapphyrin for DNA has been deter 
mined to be on the order of 10M and evidence shows that 
the mode of DNA binding is not intercalation or groove 
binding. The inventors will extend these findings and con 
struct, using all the available experimental evidence, com 
puter models of the sapphyrin-DNA interaction. These mod 
els will allow the design and engineering of covalently 
linked multimeric sapphyrin molecules with increased affin 
ity and specificity. 
These second-generation multimeric sapphyrin-based 
constructs should have a DNA affinity high enough to 
interfere with biological processes such as transcription and 
translation. It is contemplated that this will ultimately lead 
to the development of sapphyrin-based therapeutic agents 
for use in treating a variety of human diseases, including 
CaCC. 
Sapphyrin molecules themselves are also contemplated 
for use directly as chemotherapeutic agents. Currently avail 
able chemotherapeutics generally have complex structures, 
or complicated modes of interaction with their targets, that 
preclude systematic improvement. The development of a 
novel class of DNA binding compounds, namely the sap 
phyrins of the present invention, therefore provides impor 
tant new opportunities for the development and use of novel 
therapeutic agents. 
Due to the unique mode of sapphyrin-DNA interaction, 
the sapphyrin molecule possesses an unrivaled ability to act 
as a general DNA binding platform. Binding can also be 
modified so as to adjust both target cell specificity and 
degree of interaction with the DNA. For sapphyrins, impor 
tantly, the basic site of interaction with the DNA involves the 
interior of the sapphyrin macrocycle, so that the exterior 




significantly disrupting the DNA binding interaction. These 
exterior positions can be used to systematically adjust fea 
tures such as solubility, membrane permeability and cell 
selectivity. Furthermore, groups designed to modulate inter 
action with DNA can be attached to the exterior of the 
Sapphyrins including alkylating functions (bromoacetamido 
groups, epoxides etc.) to provide covalent attachment to 
DNA or ene-diyne moieties to allow for double stranded 
DNA cleavage. 
While the compositions and methods of this invention 
have been described in terms of preferred embodiments, it 
will be apparent to those of skill in the art that variations may 
be applied to the composition, methods and in the steps or 
in the sequence of steps of the method described herein 
without departing from the concept, spirit and scope of the 
invention. More specifically, it will be apparent that certain 
agents which are both chemically and physiologically 
related may be substituted for the agents described herein 
while the same or similar results would be achieved. For 
example, other macrocyclic, positively-charged entities can 
be envisioned as binding to phosphate-containing species 
such as nucleotides, oligonucleotides and DNA by means of 
the same or similar oriented electrostatic interactions 
described herein. All such similar substitutes and modifica 
tions apparent to those skilled in the art are deemed to be 
within the spirit, scope and concept of the invention as 
defined by the appended claims. 
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wherein each of R-R'' are independently hydrogen, alkyl, 
alkene, alkyne, halide, alkylhalide, hydroxyalkyl, hydroxy 
alkylamido, glycol, polyglycol, thiol, thioalkyl, aminoalkyl, 
carboxyalkyl, carboxyamidealkyl, oxyalkyl, alkoxyalkyl, 
aryloxyalkyl, oxyhydroxyalkyl, alkyloxycarbonyl, aryloxy 
carbonyl, aldehyde, ether, ketone, carboxylic acid, phos 
phate, phosphonate, sulfate, phosphate substituted alkyl, 
phosphonate substituted alkyl, or sulfate substituted alkyl, 
such that the total number of carbon atoms in each Substitu 
ent R is less than or equal to 100; 
wherein at least one of R-R' is of the formula (CH)- 
A-(CH2)-B, where 
A is alkyl having from 1-4 carbon atoms, oxy, sulfide, 
amide, carbonyl, alkenyl, alkynyl, alkylhalide, 
hydroxyalkyl, glycol, polyglycol, alkylthiol, substi 
tuted alkyl, phosphate, phosphonate, sulfate, phosphate 
substituted alkyl, phosphonate substituted alkyl, sulfate 
substituted alkyl, carboxy, carboxyamide, ester, thiol 
substituted carboxyamide, or derivatized carboxya 
mide, 
B is hydroxy, hydroxyalkyl, oxyalkyl, carboxy, carboxy 
alkyl, glycol, polyglycol, thiol, aminoalkyl, phosphate, 
phosphonate, sulfate, phosphate substituted alkyl, 
phosphonate substituted alkyl, sulfate substituted alkyl, 
substituted hydroxyalkyl, saccharide, saccharide 
derivative, or polysaccharide; and 
n and m are independently an integer from 0 to 4. 
2. The water-soluble sapphyrin of claim 1, wherein 
A is alkyl having 1-4 carbon atoms, oxy, sulfide, amide, 
carbonyl, carboxy, carboxyamide, ester, thiol-substi 
tuted carboxyamide, or derivatized carboxyamide; and 
B is hydroxy, hydroxyalkyl, saccharide, saccharide 
derivative or polysaccharide. 
3. The water-soluble sapphyrin of claim 1, wherein B is 
hydroxyalkyl. 
4. The water-soluble sapphyrin of claim 3 wherein the 
hydroxyalkyl is hydroxymethyl, hydroxyethyl, hydroxypro 
pyl, or hydroxybutyl. 
5. The water-soluble sapphyrin of claim 1 wherein A is 
carboxyamide and B is hydroxyalkyl. 
6. The water-soluble sapphyrin of claim 1 wherein A is 
oxy and B is oxyalkyl. 
7. The water-soluble sapphyrin of claim 1 wherein A is 
alkenyl and B is hydroxy. 
8. The water-soluble sapphyrin of claim 1 wherein A is 
carboxyamide and B is saccharide. 
9. The water-soluble sapphyrin of claim 1, further defined 
as having substituents R, R-RandR as set forth in Table 
2 or 3. 
10. The water-soluble sapphyrin of claim 2, where B is 
saccharide or saccharide derivative. 
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11. The water-soluble sapphyrin of claim 10, wherein the 
saccharide or saccharide derivative is selected from those Set 
forth in Table 1. 
12. The water-soluble sapphyrin of claim 1, where B is a 
polysaccharide. 
13. The water-soluble sapphyrin of claim 12, where the 
polysaccharide is chitosan, alginic acid, hyaluronic acid or 
dextran. 
14. The water-soluble sapphyrin of claim 1, wherein R is 
of the formula (CH)-A-(CH2), B, where B is 
hydroxyalkyl or saccharide. 
15. The water-soluble sapphyrin of claim 14 wherein B is 
saccharide and the saccharide is D-glucose, D-mannose, 
L-mannose, or D-galactose. 




of the formula (CH), A-(CH2)-B, where B is 
hydroxyalkyl or saccharide. 
17. The water-soluble sapphyrin of claim 1, wherein R is 
of the formula (CH)-A-(CH2)-B, where B is 
hydroxyalkyl or saccharide. 
18. The water-soluble sapphyrin of claim 1, wherein R is 
of the formula (CH), A-(CH2)-B, where B is car 
boxyalkyl. 
19. The water-soluble sapphyrin of claim 1, wherein R is 
of the formula (CH)-A-(CH2)-B, where B is car 
boxyalkyl. 
20. A water-soluble sapphyrin selected from sapphyrins 
A1-A27 of Table 2 or B1-B8 of Table 3. 
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